Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely ...

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

(Reuters) - Contract drug manufacturer Catalent, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share.

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50. David Windley has given his Hold rating due to a combination ...

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ...